Company: BNBX
Filing Date: 2025-01-17
Form Type: 424B3
Source: 0001104659-25-004510
Chunk: 9

Company: BNB PLUS CORP.
Filing Date: 2025-01-17
Form: 424B3
Chunk 9
---
 templates alone, while also providing a more competitive offering
to the mRNA manufacturing market. Currently, Linea RNAP is produced for the Company under an ISO 13485 quality system by Alphazyme, LLC
(“Alphazyme”) a third-party CDMO located in the United States, which the Company believes is sufficient for early-stage clinical
use of the enzyme. In conjunction with Alphazyme, the Company recently completed manufacturing process development work on its Linea
RNAP to increase the production scale of the enzyme and reduce unit costs.

Manufacturing Scale-up

The Company plans to offer several quality grades
of Linea DNA, each of which will have different permitted uses.

| Quality                
 Grade                  |    |                                        | Permitted                                                        
 Use                                                              | Company                                   
 Status                                    |
| GLP                    |    |                                        | Research                                                         
 and pre-clinical discovery                                       | Currently                                 
 available                                 |
| GMP                    
 for Starting Materials |    |                                        | DNA                                                              
 critical starting materials for the production of mRNA therapies | Planned                                   
 availability in January 2025              
 (GMP Site 1)                              |
| GMP                    |    |                                        | DNA                                                              
 biologic, drug substance and/or drug product                     | Planned                                   
 availability in first half of CY 2026 (1) 
 (GMP Site 2)                              |
|                        | -1 | Dependent                              
 on the availability of future funding. |                                                                  |                                           |

We are currently manufacturing LineaDNA pursuant
to Good Laboratory Practices (“GLP”) and have recently completed the buildout of a fit for purpose manufacturing facility
within our current Stony Brook, NY laboratory space capable of producing LineaDNA IVT templates under Good Manufacturing Practices (“GMP”)
suitable for use as a critical starting material for clinical and commercial mRNA therapeutics. We are currently conducting final certification
of the facility and anticipate full operational status by the end of January 2025 (“GMP Site 1”). Accordingly, on January
10, 2025 the Company announced its readiness to accept GMP customer orders for IVT templates to be manufactured in GMP Site 1 upon full
operation status. We also plan to offer additional capacity for LineaDNA IVT templates as well as capacity for LineaDNA materials manufactured
under GMP suitable for use as, or incorporation into, a biologic, drug substance and/or drug product, with availability expected during
the first half of calendar year